Akron creates $1.5M biomedical investment fund

2011-10-25
The City of Akron has launched a $1.5 million investment fund that’s intended to attract biomedical companies to the city. The new Akron BioInvestments Funds will target domestic and international companies that focus on orthopedics, wound healing, cardiovascular science, biomaterials, health information technology and medical devices, according to a statement from the city. Akron Mayor Don Plusquellic announced new details about the fund Tuesday at the annual meeting of Clevleand-based, state-backed venture development group JumpStart. However, Plusquellic first discussed the fund in March during his state of the city address. Most of the initial investments in the fund were made by Medical Mutual of Ohio, First Energy, Northeast Ohio Medical University and Akron-based Cascade Capital, which will also manage the fund. Medical Mutual contributed $1 million of the initial amount, Plusquellic said. All companies that receive investments from the fund must commit to maintaining a presence in Akron. The Akron BioInvestment Funds will consist of two parts: a rapid commercialization loan fund that’s intended for companies close to commercialization and a product development fund to support startups with proofs of concept, prototypes and market assessments. Akron is looking to build on some recent success, having recently announced that an Israeli back-pain device company, Nervomatrix, is planning to set up its North American sales and marketing headquarters in the city. Nervomatrix received a $3.5 million series A investment from Akron-based venture firm Everett Partners. The fund will begin accepting applications on Dec. 1.
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。